

FOR IMMEDIATE RELEASE

**NANCY LYNN NAMED EXECUTIVE VICE PRESIDENT
OF THE
ALZHEIMER'S DRUG DISCOVERY FOUNDATION**

NEW YORK – September 28, 2009 - Nancy Lynn has been appointed Executive Vice President of the Alzheimer's Drug Discovery Foundation, founded and co-chaired by Leonard and Ronald Lauder. The appointment, which will be effective as of October 5, 2009, was announced by Executive Director, Howard Fillit. In her new position, Ms. Lynn will be responsible for strategic planning, fundraising, board development, public relations, and marketing.

“Nancy Lynn brings an ideal background of non-profit sector experience, human health-related board service, business development, fundraising, and strategic thinking to help advance this vital and growing foundation. We are delighted to have this seasoned professional join our team as the ADDF pursues its mission to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure Alzheimer's disease, related dementias, and cognitive aging,” said Dr. Fillit.

Prior to joining the ADDF, Ms. Lynn worked for eleven years at the American Museum of Natural History in New York City (1998 – 2009). Her service at the Museum included positions as Director of Corporate Relations, Director of Global Business Development, and Senior Exhibition Developer. From 1996 – 2004, she was a regular staff lecturer at the Cloisters, the branch of the Metropolitan Museum of Art devoted to the art and architecture of medieval Europe.

Ms. Lynn is a Member of the National Board of Trustees for the Crohn's and Colitis Foundation of America and a former member of the Board of Trustees for the Martha Graham Dance Company, New York. She has served on leadership boards for the National Center for Science Education, the National Foundation for Advancement in the Arts, and the Jewish National Fund.

Ms. Lynn received a bachelor of arts in the history of art and architecture from Columbia University in New York (*Valedictorian*), and her master's degree in the history of art and architecture from the Institute of Fine Arts, New York University.

Ms. Lynn resides in Demarest, New Jersey, with her husband and 5-year-old daughter.

About the Alzheimer's Drug Discovery Foundation (ADDF)

ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 2,000 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than \$36 million to fund more than 270 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries. The ADDF website explores headline news on Alzheimer's disease, updated weekly.

###